“This is a procedure that’s done once, and it keeps giving a benefit over time,” one researcher said. “This is going to prevent thousands of strokes.”

Researchers emphasized the importance of these findings, noting that hypertension can lead to significant cardiovascular complications.

The team's AI-based fractional flow reserve calculations achieved a strong area under the curve, sensitivity and specificity. 

The new analysis, published in the Journal of the American College of Cardiology, included findings from more than 1,000 Medicare patients with rheumatic aortic stenosis.

After two years, TAVR was still linked to a reduction in the study’s primary endpoint, but it was also associated with a greater risk of valve thrombosis.

According to new data from the ongoing COMMENCE clinical trial, patients showed no signs of structural valve deterioration after five years.

Researchers noted that these patients received care in the same hospitals and were treated by the same physicians. So why the difference in outcomes? 

Specialists from the American College of Cardiology and Society of Thoracic Surgeons explored data from more than 276,000 patients who have undergone a TAVR procedure in the last nine years.